Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Institute for Medical Microbiology, Virology and Hygiene, Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
Sci Rep. 2020 Oct 29;10(1):18588. doi: 10.1038/s41598-020-73356-x.
Despite improvements in diagnosis, intensive-care medicine and surgical technique, the mortality of patients with secondary peritonitis is still high. Early and aggressive empiric antibiotic treatment has strong impact on the outcome. This retrospective study investigates bacterial and fungal pathogens and their antibiotic sensitivity in patients with secondary peritonitis. All patients that underwent emergency laparotomy due to secondary peritonitis at the Department of Surgery, University Medical Center Hamburg-Eppendorf between 2005 and 2015 were reviewed and overall 414 patients were included. We correlated the intra-abdominal localization of the organ perforation with intraoperative microbiological findings and corresponding sensitivities to relevant antibiotics. Overall, the most common findings were Escherichia coli (39%) and other Enterobacterica (24%). Depending on the location of the perforation, Cefuroxime/Metronidazole and Cefutaxime/Metronidazole were effective (based on in vitro susceptibility testing) in only 55-73% of the patients, while Meropenem/Vancomycin was able to control the peritonitis in more than 98% of the patients; independent of the location. Besides early source control, appropriate empiric treatment plays a pivotal role in treatment of secondary peritonitis. We are able to show that the frequently used combinations of second or third generation Cephalosporins with Metronidazole are not always sufficient, which is due to the biological resistance of the bacteria. Further clinical studies are needed to determine whether calculated use of broad-spectrum antibiotics with a sensitivity rate > 99%, such as Carbapenem plus Vancomycin, can improve overall survival rates in critically ill patients with secondary peritonitis.
尽管在诊断、重症监护医学和外科技术方面有所改进,但继发性腹膜炎患者的死亡率仍然很高。早期和积极的经验性抗生素治疗对预后有很大的影响。本回顾性研究调查了继发性腹膜炎患者的细菌和真菌病原体及其抗生素敏感性。2005 年至 2015 年间,因继发性腹膜炎在汉堡大学医学中心外科接受急诊剖腹手术的所有患者均进行了回顾性研究,共纳入 414 例患者。我们将腹腔内器官穿孔的部位与术中微生物学发现和相应的抗生素敏感性进行了相关性分析。总体而言,最常见的病原体是大肠杆菌(39%)和其他肠杆菌科(24%)。根据穿孔的位置,头孢呋辛/甲硝唑和头孢噻肟/甲硝唑在 55-73%的患者中有效(基于体外药敏试验),而美罗培南/万古霉素能控制 98%以上的患者的腹膜炎;与穿孔位置无关。除了早期的源头控制,适当的经验性治疗在治疗继发性腹膜炎中起着关键作用。我们能够证明,经常使用第二代或第三代头孢菌素与甲硝唑联合治疗并不总是足够的,这是由于细菌的生物学耐药性。需要进一步的临床研究来确定是否可以计算使用广谱抗生素,如碳青霉烯类加万古霉素,是否可以提高重症继发性腹膜炎患者的总体生存率。